Submit a comment

Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice
Atsuhito Nakao, Makiko Fujii, Ryutaro Matsumura, Kotaro Kumano, Yasushi Saito, Kohei Miyazono, Itsuo Iwamoto
Atsuhito Nakao, Makiko Fujii, Ryutaro Matsumura, Kotaro Kumano, Yasushi Saito, Kohei Miyazono, Itsuo Iwamoto
View: Text | PDF
Article

Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice

Abstract

TGF-β plays an important role in lung fibrosis, which is a major cause of suffering and death seen in pulmonary disease. Smad7 has been recently identified as an antagonist of TGF-β signaling. To investigate whether this novel molecule can be exploited for therapy of lung fibrosis, we determined the effect of exogenous Smad7, introduced by a recombinant human type 5 adenovirus vector, on bleomycin-induced lung fibrosis in mice. C57BL/6 mice with bleomycin-induced lungs received an intratracheal injection of a recombinant adenovirus carrying mice Smad7 cDNA. These mice demonstrated suppression of type I precollagen mRNA, reduced hydroxyproline content, and no morphological fibrotic responses in the lungs when compared with mice administered adenovirus carrying Smad6 cDNA. In addition, we found that expression of Smad7 transgene blocked Smad2 phosphorylation induced by bleomycin in mouse lungs. These data indicated that gene transfer of Smad7 (but not Smad6) prevented bleomycin-induced lung fibrosis, suggesting that Smad7 may have applicability in the treatment of pulmonary fibrosis.

Authors

Atsuhito Nakao, Makiko Fujii, Ryutaro Matsumura, Kotaro Kumano, Yasushi Saito, Kohei Miyazono, Itsuo Iwamoto

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required